Home News General Health News Purdue Pharma Tentatively Reaches Settlement in Opioid Lawsuits

Purdue Pharma Tentatively Reaches Settlement in Opioid Lawsuits

Deal is said to be worth $10 billion to $12 billion; company will not admit to wrongdoing

WEDNESDAY, Sept. 11, 2019 (HealthDay News) — OxyContin maker Purdue Pharma has reached a tentative settlement with a coalition of states and local governments that sued the company over its role in America’s ongoing opioid crisis, press reports say.

The settlement requires the dissolution of Purdue Pharma and the formation of a new company that would continue to sell OxyContin, the firm’s blockbuster opioid, The New York Times reported. Proceeds from the new company would be used to pay the plaintiffs in the lawsuit and combat the opioid epidemic. Purdue also would donate drugs under development for addiction treatment and overdose reversal.

The family that holds a controlling interest in Purdue Pharma, the Sacklers, would be required to relinquish their hold on the company, The Washington Post said. The deal is said to be worth $10 billion to $12 billion, including a $3 billion payment from the Sacklers over seven years, the Times and the Post reported.

The settlement would not contain any statement of wrongdoing. The executive committee of 22 states and more than 2,000 cities and counties taking part in the federal lawsuit is recommending that the deal be accepted, the Times said. The settlement comes about six weeks before the start of the first federal trial related to the opioid epidemic lawsuits. The trial is slated to take place before a federal judge in Cleveland who has issued tough pretrial rulings against Purdue and the Sacklers, the Times noted, darkening the company’s prospects in court. Meanwhile, more than 40 individual lawsuits against drug companies are making their way through state courts as are some lawsuits targeting the Sacklers personally, the Post reported.

The New York Times Article

The Washington Post Article

Copyright © 2019 HealthDay. All rights reserved.